{
    "nctId": "NCT01483300",
    "briefTitle": "Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Overall response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed metastatic breast cancer\n* Disease progression during or after previous 1st line chemotherapy\n* Scheduled to receive 2nd line chemotherapy.\n* Measurable disease, defined as a least one lesion that can be accurately measured in at least one dimension\n* 18 years of age or older\n* ECOG performance status of 0-2\n* Life expectancy of greater than 6 months\n\nExclusion Criteria:\n\n* Previous treatment with one of the study drugs\n* Application of other cytotoxic chemotherapy or radiotherapy\n* Insufficent renal function (creatinine clearance \\< 60ml/min)\n* Clinically unstable brain metastasis\n* Pregancy or lactation\n* History of other malignancy within last 5 years.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}